The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity

Claudia Afferni, Carla Buccione, Sara Andreone, Maria Rosaria Galdiero, Gilda Varricchi, Gianni Marone, Fabrizio Mattei, Giovanna Schiavoni

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Interleukin-33 (IL-33) is a IL-1 family member of cytokines exerting pleiotropic activities. In the steady-state, IL-33 is expressed in the nucleus of epithelial, endothelial, and fibroblast-like cells acting as a nuclear protein. In response to tissue damage, infections or necrosis IL-33 is released in the extracellular space, where it functions as an alarmin for the immune system. Its specific receptor ST2 is expressed by a variety of immune cell types, resulting in the stimulation of a wide range of immune reactions. Recent evidences suggest that different IL-33 isoforms exist, in virtue of proteolytic cleavage or alternative mRNA splicing, with potentially different biological activity and functions. Although initially studied in the context of allergy, infection, and inflammation, over the past decade IL-33 has gained much attention in cancer immunology. Increasing evidences indicate that IL-33 may have opposing functions, promoting, or dampening tumor immunity, depending on the tumor type, site of expression, and local concentration. In this review we will cover the biological functions of IL-33 on various immune cell subsets (e.g., T cells, NK, Treg cells, ILC2, eosinophils, neutrophils, basophils, mast cells, DCs, and macrophages) that affect anti-tumor immune responses in experimental and clinical cancers. We will also discuss the possible implications of diverse IL-33 mutations and isoforms in the anti-tumor activity of the cytokine and as possible clinical biomarkers.

Original languageEnglish
JournalFrontiers in Immunology
Volume9
Issue numberNOV
DOIs
Publication statusPublished - Nov 13 2018

Fingerprint

Immunity
Neoplasms
T-Lymphocyte Subsets
Protein Isoforms
Cytokines
Basophils
Interleukin-33
Alternative Splicing
Extracellular Space
Regulatory T-Lymphocytes
Nuclear Proteins
Infection
Allergy and Immunology
Interleukin-1
Eosinophils
Mast Cells
Natural Killer Cells
Immune System
Hypersensitivity
Neutrophils

Keywords

  • Cancer
  • IL-33
  • IL-33 isoforms
  • Immune cell subsets
  • Tumor immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. / Afferni, Claudia; Buccione, Carla; Andreone, Sara; Galdiero, Maria Rosaria; Varricchi, Gilda; Marone, Gianni; Mattei, Fabrizio; Schiavoni, Giovanna.

In: Frontiers in Immunology, Vol. 9, No. NOV, 13.11.2018.

Research output: Contribution to journalReview article

Afferni, Claudia ; Buccione, Carla ; Andreone, Sara ; Galdiero, Maria Rosaria ; Varricchi, Gilda ; Marone, Gianni ; Mattei, Fabrizio ; Schiavoni, Giovanna. / The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. In: Frontiers in Immunology. 2018 ; Vol. 9, No. NOV.
@article{86fd15035ba7410aaa645f22e5f87d1f,
title = "The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity",
abstract = "Interleukin-33 (IL-33) is a IL-1 family member of cytokines exerting pleiotropic activities. In the steady-state, IL-33 is expressed in the nucleus of epithelial, endothelial, and fibroblast-like cells acting as a nuclear protein. In response to tissue damage, infections or necrosis IL-33 is released in the extracellular space, where it functions as an alarmin for the immune system. Its specific receptor ST2 is expressed by a variety of immune cell types, resulting in the stimulation of a wide range of immune reactions. Recent evidences suggest that different IL-33 isoforms exist, in virtue of proteolytic cleavage or alternative mRNA splicing, with potentially different biological activity and functions. Although initially studied in the context of allergy, infection, and inflammation, over the past decade IL-33 has gained much attention in cancer immunology. Increasing evidences indicate that IL-33 may have opposing functions, promoting, or dampening tumor immunity, depending on the tumor type, site of expression, and local concentration. In this review we will cover the biological functions of IL-33 on various immune cell subsets (e.g., T cells, NK, Treg cells, ILC2, eosinophils, neutrophils, basophils, mast cells, DCs, and macrophages) that affect anti-tumor immune responses in experimental and clinical cancers. We will also discuss the possible implications of diverse IL-33 mutations and isoforms in the anti-tumor activity of the cytokine and as possible clinical biomarkers.",
keywords = "Cancer, IL-33, IL-33 isoforms, Immune cell subsets, Tumor immunology",
author = "Claudia Afferni and Carla Buccione and Sara Andreone and Galdiero, {Maria Rosaria} and Gilda Varricchi and Gianni Marone and Fabrizio Mattei and Giovanna Schiavoni",
year = "2018",
month = "11",
day = "13",
doi = "10.3389/fimmu.2018.02601",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S.A.",
number = "NOV",

}

TY - JOUR

T1 - The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity

AU - Afferni, Claudia

AU - Buccione, Carla

AU - Andreone, Sara

AU - Galdiero, Maria Rosaria

AU - Varricchi, Gilda

AU - Marone, Gianni

AU - Mattei, Fabrizio

AU - Schiavoni, Giovanna

PY - 2018/11/13

Y1 - 2018/11/13

N2 - Interleukin-33 (IL-33) is a IL-1 family member of cytokines exerting pleiotropic activities. In the steady-state, IL-33 is expressed in the nucleus of epithelial, endothelial, and fibroblast-like cells acting as a nuclear protein. In response to tissue damage, infections or necrosis IL-33 is released in the extracellular space, where it functions as an alarmin for the immune system. Its specific receptor ST2 is expressed by a variety of immune cell types, resulting in the stimulation of a wide range of immune reactions. Recent evidences suggest that different IL-33 isoforms exist, in virtue of proteolytic cleavage or alternative mRNA splicing, with potentially different biological activity and functions. Although initially studied in the context of allergy, infection, and inflammation, over the past decade IL-33 has gained much attention in cancer immunology. Increasing evidences indicate that IL-33 may have opposing functions, promoting, or dampening tumor immunity, depending on the tumor type, site of expression, and local concentration. In this review we will cover the biological functions of IL-33 on various immune cell subsets (e.g., T cells, NK, Treg cells, ILC2, eosinophils, neutrophils, basophils, mast cells, DCs, and macrophages) that affect anti-tumor immune responses in experimental and clinical cancers. We will also discuss the possible implications of diverse IL-33 mutations and isoforms in the anti-tumor activity of the cytokine and as possible clinical biomarkers.

AB - Interleukin-33 (IL-33) is a IL-1 family member of cytokines exerting pleiotropic activities. In the steady-state, IL-33 is expressed in the nucleus of epithelial, endothelial, and fibroblast-like cells acting as a nuclear protein. In response to tissue damage, infections or necrosis IL-33 is released in the extracellular space, where it functions as an alarmin for the immune system. Its specific receptor ST2 is expressed by a variety of immune cell types, resulting in the stimulation of a wide range of immune reactions. Recent evidences suggest that different IL-33 isoforms exist, in virtue of proteolytic cleavage or alternative mRNA splicing, with potentially different biological activity and functions. Although initially studied in the context of allergy, infection, and inflammation, over the past decade IL-33 has gained much attention in cancer immunology. Increasing evidences indicate that IL-33 may have opposing functions, promoting, or dampening tumor immunity, depending on the tumor type, site of expression, and local concentration. In this review we will cover the biological functions of IL-33 on various immune cell subsets (e.g., T cells, NK, Treg cells, ILC2, eosinophils, neutrophils, basophils, mast cells, DCs, and macrophages) that affect anti-tumor immune responses in experimental and clinical cancers. We will also discuss the possible implications of diverse IL-33 mutations and isoforms in the anti-tumor activity of the cytokine and as possible clinical biomarkers.

KW - Cancer

KW - IL-33

KW - IL-33 isoforms

KW - Immune cell subsets

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=85056663985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056663985&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.02601

DO - 10.3389/fimmu.2018.02601

M3 - Review article

C2 - 30483263

AN - SCOPUS:85056663985

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - NOV

ER -